Transplacental passage of antinuclear antibody. Study in infants of mothers with systemic lupus erythematosus

1966 ◽  
Vol 93 (6) ◽  
pp. 656-663 ◽  
Author(s):  
J. S. Beck
2019 ◽  
Vol 71 (7) ◽  
pp. 893-902 ◽  
Author(s):  
May Y. Choi ◽  
Ann E. Clarke ◽  
Yvan St. Pierre ◽  
John G. Hanly ◽  
Murray B. Urowitz ◽  
...  

2002 ◽  
Vol 9 (2) ◽  
pp. 287-294 ◽  
Author(s):  
Liping Du ◽  
Sachiko Fukushima ◽  
Annahita Sallmyr ◽  
Rolf Manthorpe ◽  
Anders Bredberg

ABSTRACT This study of stress-related antinuclear antibody (ANA) reactivity was undertaken with the objective of improving clinical ANA testing. ANA was determined by parallel enzyme-linked immunosorbent assays of crude nuclear protein antigen extracted from HEp-2 cells either grown under optimal conditions (providing nonstress ANA antigen) or exposed to stress (providing stress ANA antigen). The stress stimuli used were gamma radiation (causing DNA damage) and a hypertonic environment (causing apoptosis). Signs of stress-related ANA reactivity were seen among connective tissue disease (CTD) patients (including patients with systemic lupus erythematosus; mixed CTD; calcinosis, Reynaud's phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia; scleroderma; and Sjögren's syndrome): 11% showed stress-positive ANA (i.e., a significantly stronger ANA reactivity with the extract from stressed cells), whereas 21% showed a markedly weaker reaction with the stress antigen. In contrast, among ANA screening patient sera, with no diagnosis of CTD, the fraction showing stress-positive ANA was higher (7 to 8%, depending on the type of stress) than among those showing a lower reactivity with stress antigen (1.5 to 2.5%). Only one serum among 89 (1%) tested sera from healthy individuals showed a stress-related ANA reaction. This demonstration of stress-related ANA suggests a means to improve the performance of clinical ANA testing.


1981 ◽  
Vol 98 (4) ◽  
pp. 578-581 ◽  
Author(s):  
J.P. Gillespie ◽  
C.B. Lindsley ◽  
M.A. Linshaw ◽  
W.P. Richardson

Lupus ◽  
2020 ◽  
Vol 29 (7) ◽  
pp. 697-704 ◽  
Author(s):  
Oh Chan Kwon ◽  
Yong-Gil Kim ◽  
Jung Hwan Park ◽  
Min-Chan Park

Objective To evaluate the rate of seroconversion to antinuclear-antibody negativity in patients with systemic lupus erythematosus and its association with subsequent systemic lupus erythematosus flare risk. Methods Medical records of patients with systemic lupus erythematosus with positive antinuclear antibodies (titer ≥1 : 40) at diagnosis and at least one repeat antinuclear antibody test were reviewed. We determined the frequency of seroconversion to antinuclear antibody negativity among these patients and investigated whether seroconversion to antinuclear antibody negativity was associated with subsequent systemic lupus erythematosus flare risk. The seroconversion to antinuclear antibody negativity was defined as a conversion of positive antinuclear antibodies to a titer below the cut-off of 1 : 40. Systemic lupus erythematosus flare was defined as one new British Isles Lupus Assessment Group A or two new British Isles Lupus Assessment Group B domain scores. To estimate hazard ratios and 95% confidence intervals for systemic lupus erythematosus flare according to seroconversion to antinuclear antibody negativity, Cox regression analysis with adjustment for known systemic lupus erythematosus flare risk factors was performed. Kaplan-Meier analysis was used to compare flare-free survival rates between negative converters and non-converters. Results Among the total 175 patients, seroconversion to antinuclear antibody negativity was found in 17 (9.7%) patients in a median 53.5 (range: 25.7–84.0) months. After the last antinuclear antibody tests, 53 systemic lupus erythematosus flare cases were identified during 14.3 (range: 8.2–21.7) months of follow-up. Systemic lupus erythematosus flare risk was significantly lower in patients with negatively seroconverted antinuclear antibodies (adjusted hazard ratio 0.13, 95% confidence interval 0.03–0.58, p = 0.007). Kaplan-Meier analysis showed significantly higher flare-free survival in negative converters than in non-converters ( p = 0.004). Conclusion Seroconversion to antinuclear antibody negativity occurred in 9.7% of patients over 53.5 months and was associated with a lower future systemic lupus erythematosus flare risk.


2018 ◽  
Vol 78 (8) ◽  
pp. e76-e76 ◽  
Author(s):  
Philippe Willems ◽  
Ellen De Langhe ◽  
René Westhovens ◽  
Steven Vanderschueren ◽  
Daniel Blockmans ◽  
...  

2019 ◽  
Vol 7 ◽  
pp. 2050313X1987178 ◽  
Author(s):  
Teruhiro Fujii ◽  
Yuko Iwabuchi ◽  
Takahito Moriyama ◽  
Keiko Uchida ◽  
Kosaku Nitta

Lemierre syndrome develops in healthy young patients as a result of bacteremia after oral cavity infection. It causes thrombophlebitis in the internal jugular vein. Infection can easily occur during immunosuppressive treatment in patients with systemic lupus erythematosus and become severe. We present a case of Lemierre syndrome in a patient with systemic lupus erythematosus. A 56-year-old woman presented with fever, left lower toothache, and skin symptoms from the left neck to the anterior chest. Clinical presentation and laboratory investigations revealed Lemierre syndrome. The inflammation and thrombus disappeared with antibiotic and anticoagulant therapies. However, transient hypocomplementemia and elevated antinuclear antibody levels were observed during treatment; therefore, a concomitant systemic lupus erythematosus flare was considered. In systemic lupus erythematosus patients with Lemierre syndrome, complement and antinuclear antibody levels are modified, so other indicators should be precisely evaluated, such as levels of urinary protein, sediment, serum creatinine and anti-dsDNA antibody, and systemic lupus erythematosus disease activity index.


Sign in / Sign up

Export Citation Format

Share Document